---
title: "Savara Inc. (SVRA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SVRA.US.md"
symbol: "SVRA.US"
name: "Savara Inc."
industry: "Biotechnology"
datetime: "2026-04-17T07:14:10.650Z"
locales:
  - [en](https://longbridge.com/en/quote/SVRA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SVRA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SVRA.US.md)
---

# Savara Inc. (SVRA.US)

## Company Overview

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.savarapharma.com](https://www.savarapharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -9.66 | 444 | - | - | - |
| PB | 5.65 | 328 | 12.33 | 6.07 | 3.70 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-16T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 75% |
| Overweight | 2 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.64 |
| Highest Target | 16.00 |
| Lowest Target | 9.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SVRA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SVRA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SVRA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SVRA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**